Scandinavian Biopharma Holding

Scandinavian Biopharma is a private, clinical-stage biopharma company specializing in vaccine development and distribution. Its lead asset, ETVAX®, is an oral vaccine candidate for ETEC diarrhea, which has completed a successful Phase 2b trial and is positioned for Phase 3. The company operates with a hybrid model, advancing its proprietary pipeline while also distributing specialty biopharma products, placing it in the 'Early Revenue' stage as it progresses its flagship program toward pivotal studies.

Oral, inactivated whole-cell vaccine platform utilizing a recombinant mucosal adjuvant (LTB) to stimulate gut immunity.

ETVAX® is the most advanced ETEC vaccine candidate globally, giving it a potential first-mover advantage. Competition may come from other biotechs or large pharma companies developing alternative ETEC vaccine approaches, but none are publicly known to be as close to Phase 3. The primary competitive threat in the near term is for funding and partnership attention.